Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity

Launched by JOSEPH SFERRA · Apr 30, 2019

Keywords

ClinConnect Summary

This clinical trial is studying whether a medication called calcitonin can help improve the results of a special imaging test called SPECT-CT for patients with primary hyperparathyroidism, a condition that causes high levels of calcium in the blood. The study aims to see if lowering calcium levels with calcitonin before the imaging test will help doctors better locate the parathyroid adenoma, which is a growth that can cause these high calcium levels.

To participate in this trial, patients must have been diagnosed with primary hyperparathyroidism, have had a SPECT-CT scan within the last year that did not show clear results, and be looking for surgery to treat their condition. Eligible participants will receive calcitonin and then undergo a second SPECT-CT scan to see if the results improve. It's important to note that there are specific criteria for joining, including not having certain allergies or medical conditions. If you or a loved one are considering this trial, you can expect close monitoring and support throughout the process.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of primary hyperparathyroidism
• • Non-localizing SPECT-CT performed within 365 days prior to consent to participate in study
• • Patient desires surgical intervention for treatment of PHPT
• • No contraindications to 99mTC-Sestamibi
• • No contraindications to treatment with calcitonin
• • Serum calcium level prior to non-localizing SPECT-CT is ≥10.5 mg/dL
• • Patient consents to participate and undergo second SPECT-CT for purposes of research
• Exclusion Criteria:
• • Previous surgery to the neck, including resection of parathyroid tissue, except where end organ damage is present and further surgical intervention is medically necessary
• • Contraindication to 99mTC-Sestamibi SPECT-CT as evidenced by allergic reaction or adverse event during index SPECT-CT
• • Allergy to calcitonin
• • Hypocalcemia (contraindication to calcitonin)
• • Vitamin D deficiency (contraindication to calcitonin)
• • Previous treatment with radioactive iodine
• • New prescription of thyroid medication (levothyroxine, armour thyroid tablets, etc. must be taken at time of index scan and research scan)
• • Lithium exposure within one year of SPECT-CT (index and research scans)
• • Secondary hyperparathyroidism
• • Benign familial hypocalciuric hypercalcemia
• • Known malignancy, particularly multiple endocrine neoplasia
• • New prescription of thiazide diuretic, (thiazide diuretic must have been taken at the time of index scan and second scan)
• • Currently taking calcium channel blockers
• • Pregnancy